LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

Home・Akciju saraksts・Roivant Sciences Ltd

Roivant Sciences Ltd

Slēgts

SektorsVeselības aprūpe

27.83 -2.66

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

27.83

Max

28.12

Galvenie mērījumi
By Trading Economics
Ienākumi	-200M -314M
Pārdošana	428K 2M
Peļņas marža	-15,692.896
Darbinieki	750
EBITDA	-132M -290M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+22.36% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	5B 20B
Iepriekšējā atvēršanas cena	30.49
Iepriekšējā slēgšanas cena	27.83

Ziņu noskaņojums

By Acuity

67%

33%

310 / 347 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

11 / 11.18 Atbalsts un pretestība

Roivant Sciences Ltd Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. maijs 23:43 UTC

Galvenie ziņu notikumi

New Zealand's Unemployment Rate Falls in 1Q

2026. g. 5. maijs 23:20 UTC

Karstas akcijas

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

2026. g. 5. maijs 21:48 UTC

Peļņas

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

2026. g. 5. maijs 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

2026. g. 6. maijs 00:00 UTC

Tirgus saruna

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

2026. g. 5. maijs 23:39 UTC

Tirgus saruna

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

2026. g. 5. maijs 22:26 UTC

Tirgus saruna

AMD Data-Center Business Continues to Surge -- Market Talk

2026. g. 5. maijs 22:20 UTC

Tirgus saruna

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

2026. g. 5. maijs 22:08 UTC

Peļņas

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

2026. g. 5. maijs 22:07 UTC

Peļņas

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026. g. 5. maijs 21:48 UTC

Peļņas

Pan American Silver 1Q Adj EPS $1.09 >PAAS

2026. g. 5. maijs 21:48 UTC

Peļņas

Pan American Silver 1Q Rev $1.2B >PAAS

2026. g. 5. maijs 21:42 UTC

Peļņas

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026. g. 5. maijs 21:38 UTC

Peļņas

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026. g. 5. maijs 21:30 UTC

Peļņas

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026. g. 5. maijs 21:29 UTC

Peļņas

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026. g. 5. maijs 21:26 UTC

Peļņas

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

2026. g. 5. maijs 21:25 UTC

Peļņas

Alcon Inc. 1Q EPS 39c >ALC.EB

2026. g. 5. maijs 21:25 UTC

Peļņas

Alcon Inc. 1Q Rev $2.71B >ALC.EB

2026. g. 5. maijs 21:24 UTC

Peļņas

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026. g. 5. maijs 21:18 UTC

Peļņas

Mistras Backs 2026 Rev $730M-$750M >MG

2026. g. 5. maijs 21:17 UTC

Peļņas

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

2026. g. 5. maijs 21:15 UTC

Peļņas

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

2026. g. 5. maijs 21:12 UTC

Peļņas

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

2026. g. 5. maijs 21:11 UTC

Peļņas

SSR Mining 1Q Rev $581.8M >SSRM

2026. g. 5. maijs 21:10 UTC

Peļņas

SSR Mining 1Q Adj EPS $1.15 >SSRM

2026. g. 5. maijs 21:10 UTC

Peļņas

SSR Mining 1Q EPS $1.16 >SSRM

2026. g. 5. maijs 21:08 UTC

Peļņas

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026. g. 5. maijs 21:01 UTC

Peļņas

Intact Financial 1Q EPS C$4.12 >IFC.T

2026. g. 5. maijs 21:01 UTC

Karstas akcijas

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Salīdzinājums

Cenas izmaiņa

Roivant Sciences Ltd Prognoze

Cenas mērķis

By TipRanks

22.36% augšup

Prognoze 12 mēnešiem

Vidējais 34.7 USD 22.36%

Augstākais 41 USD

Zemākais 29 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Roivant Sciences Ltd — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Roivant Sciences Ltd — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

11 / 11.18Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Noskaņojums

By Acuity

310 / 347 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.